EDMONTON - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), trading at $4.56 and showing significant volatility with a beta of 3.27, announced Wednesday that it has completed the mailing of materials for its upcoming annual general and special meeting of shareholders scheduled for August 8, 2025.

The virtual meeting will be held at 1:00 p.m. Eastern time (11:00 a.m. Mountain Time) via webcast, allowing shareholders to participate regardless of location. The management information circular and related materials are now available on the company’s website and SEDAR+.

Shareholders of record as of June 16, 2025, are eligible to vote, with the voting deadline set for August 6, 2025. The board of directors recommends shareholders vote in favor of all director nominees and meeting resolutions.

Aurora, headquartered in Edmonton, Alberta, operates in both medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand. The company’s brand portfolio includes Drift, San Rafael ’71, and MedReleaf, among others. Aurora also maintains a controlling interest in Bevo Farms Ltd., a supplier of propagated agricultural plants.

Shareholders requiring assistance with voting can contact Aurora’s proxy solicitation agent, Laurel Hill Advisory Group.

The information in this article is based on a press release statement from Aurora Cannabis Inc.

In other recent news, Aurora Cannabis Inc. has expanded its medical cannabis compassionate pricing program in Canada, raising the income eligibility threshold to $60,000 CAD, which now encompasses over half of the adult population. This initiative aims to enhance accessibility for patients using AuroraMedical.com. Concurrently, the company has introduced new medical cannabis products, including Aurora | Mediora Minis - Cannatonic CBD Flower and Daily Special | Sativa J’s THC Pre-Rolls. Aurora Cannabis has also denied rumors of an acquisition of New Zealand-based MedLeaf Therapeutics, clarifying that no discussions or agreements have been made. The company recently filed its financial statements and management’s discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025. In Australia, Aurora has expanded its IndiMed brand with two new high-potency strains, IndiMed TEMPO 22 | Lemon Laser and IndiMed TEMPO 22 | Pickled Petrol, offering more treatment options for patients. These products are available through MedReleaf Australia, a wholly owned subsidiary. Additionally, Aurora Cannabis submitted a Form 6-K report to the U.S. Securities and Exchange Commission for June 2025, as part of its routine disclosure obligations. This filing highlights the company’s regulatory compliance but lacks specific financial or strategic details.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.